4.8.8.5Vertical

Vagal Nerve Stimulation Devices

Implantable and external VNS systems treating epilepsy.

Market snapshot

These figures describe Neurological & Neuromodulation Devices (4.8.8), the segment that Vagal Nerve Stimulation Devices sits within — not Vagal Nerve Stimulation Devices on its own.

FragmentationConsolidatedEstimate

Within electromedical apparatus (NAICS 334510); the Census Bureau does not split out neuromodulation, so the segment is not separately sized.

Business model & economics

Revenue model

Implantable device sales plus replacement and programming

Key economics

Recurring revenue
Moderate

replacement-cycle-driven

EBITDA margin
20–30%
Capex intensity
High

Characteristics

  • Chronic-pain and movement-disorder applications.
  • Expanding neuromodulation indications.
  • Implantables with replacement-cycle revenue.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Neuromodulation strategics
  • Diversified medtech platforms
  • VC-backed innovators

What’s driving deals

  • Acquisition of neuromodulation innovation.
  • Expanding indications and chronic-pain demand.
  • High-value implantable economics.

Find Vagal Nerve Stimulation Devices acquisition targets

Search Acquisera’s index for companies classified under Vagal Nerve Stimulation Devices (4.8.8.5) and build a targeted deal pipeline.

Search companies